MedPath

Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR

Not Applicable
Completed
Conditions
Functional Tricuspid Regurgitation
Interventions
Device: Pivot Balloon Catheter
Registration Number
NCT05648838
Lead Sponsor
Tau-MEDICAL Co., Ltd.
Brief Summary

Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation

Detailed Description

The study for evaluation of safety and efficacy of Pivot Balloon to monitoring acute RV failure and reduction of Functional Tricuspid Regurgitation : multi-center, open label, single arm, investigator initiated exploratory pilot study

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7
Inclusion Criteria
  • Adult males and females aged 20 years or above
  • Target of Thoracic Surgery for TR and patients above the severe level on the criteria presented in the Classification of TR Grade based on echocardiogram, among those with TR, for whom a surgical treatment has been decided
  • An individual who voluntarily agreed to the participation in the clinical trial and signed the written consent
  • An individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial
Exclusion Criteria
  • Uncontrolled hyperthyroidism
  • A recent formation of soft blood clot or embolic material
  • Uncorrected coagulopathy
  • Prohibition of anticoagulant agents
  • Previous insertion of a device such as an Implantable Cardioverter Defibrillator (ICD) or a pacemaker
  • Presence of malignant tumor or benign tumor such as myxoma in the heart
  • Presence of a symptom of active infection
  • Chronic pulmonary disease
  • Congenital tricuspid valve insufficiency
  • Pregnant or lactating mother, or a female patient planning pregnancy during the period of clinical trial, or a female not using an approved contraceptive with the possibility of pregnancy
  • Participation in another clinical trial 30 days prior to the screening
  • In addition, anyone showing a clinical finding deemed to be unsuitable for the clinical trial by the Principal Investigator or the Investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pivot BalloonPivot Balloon Cathetermornitoring with transcatheter Tricuspid Regurgitation reduction system
Primary Outcome Measures
NameTimeMethod
change of tricuspid regurgitation grade (1)immediately after the procedure

check the success of surgery /measure the size of the TR area

change of tricuspid regurgitation grade (2)immediately after the procedure

examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram

Secondary Outcome Measures
NameTimeMethod
change of tricuspid regurgitation valve hemodynamicswithin 24 h of insertion

examine the changes in the severity of tricuspid valve insufficiency with Echocardiogram

evaluate the efficacy based on the function of early diagnosis (2)within 24 h of insertion

evaluate the technical success rate of the implantation and the technical feasibility of 'Pivot Balloon'

evaluate the efficacy based on the function of early diagnosis (1)within 24 h of insertion

examine tricuspid regurgitation intolerance

Trial Locations

Locations (10)

Hallym University Medical Center

🇰🇷

Anyang, Dongan-gu, Korea, Republic of

Keimyung University Dongsan Hospital

🇰🇷

Daegu, Dalseo-gu, Korea, Republic of

Chungnam National University Hospital (CNU Hospital)

🇰🇷

Daejeon, Jung-gu, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan, Gyeongsangnamdo, Korea, Republic of

Yeungnam University Hospital

🇰🇷

Daegu, Nam-gu, Korea, Republic of

Ulsan Hospital

🇰🇷

Ulsan, Nam-gu, Korea, Republic of

Chungnam National University Sejong Hospital

🇰🇷

Sejong, Sejong-si, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Songpa-gu, Korea, Republic of

Bucheon Sejong Hospital

🇰🇷

Bucheon-si, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath